Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: EndoVascular Technologies

This article was originally published in The Gray Sheet

Executive Summary

EndoVascular Technologies: Initial Phase II study results for the firm's bifurcated EGS endovascular grafting system to treat abdominal aortic aneurysm released June 2 demonstrate a 49% decrease in hospital stay with EGS use versus standard AAA surgery. Mean hospital stay was 3.9 days for the EGS group versus 7.6 days for surgical controls. The 209 patient study included 106 EGS patients and 103 surgical control patients treated at 20 U.S. sites. Results showed that for EGS patients, the prosthesis "was successfully delivered and implanted in 96 of 106 attempted procedures, representing 90.6% primary technical success," the firm states. "The 30-day mortality rate" for the EGS group patients was 1.9% versus 3.9% for the surgical control group. Serious complications were seen in 1.9% of EGS patients and 2.9% of surgical controls. Results of the firm's tube EGS system Phase II studies were reported in January ("The Gray Sheet" Jan. 20, I&W-6)...

You may also be interested in...

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.

BioCryst’s Oral Option To Take On Injectables In HAE Prophylaxis Market

Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.

STRENGTH Results May Weaken Chances For Omega-3 Fatty Acid Heart Health Claims

Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts